Akums Drugs & Pharmaceuticals Ltd

Akums Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Akums Drugs & Pharmaceuticals Ltd

₹ 515 -2.09%
15 May 3:47 p.m.
akums.in BSE: 544222 NSE: AKUMS
About

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]

Key Points

Business Profile[1] Akums Drugs is a Contract Development and Manufacturing Organization (CDMO) manufacturing tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies.

Website BSE NSE
  • Market Cap ₹ 8,112 Cr.
  • Current Price ₹ 515
  • High / Low ₹ 623 / 409
  • Stock P/E 69.6
  • Book Value ₹ 154
  • Dividend Yield 0.00 %
  • ROCE 6.82 %
  • ROE 4.93 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Stock is trading at 3.38 times its book value
  • The company has delivered a poor sales growth of 10.0% over past five years.
  • Company has a low return on equity of 3.15% over last 3 years.
  • Earnings include an other income of Rs.106 Cr.
  • Working capital days have increased from 34.5 days to 67.3 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare Nifty500 Shariah Nifty Microcap 250 Nifty Total Market Nifty500 Equal Weight

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
316 447 383 298 317 328 337 329 332 309 369 338
503 358 351 359 274 285 303 311 288 292 344 327
Operating Profit -187 89 32 -61 44 43 34 18 44 17 25 12
OPM % -59% 20% 8% -20% 14% 13% 10% 5% 13% 5% 7% 3%
20 4 25 25 26 32 34 32 29 27 26 25
Interest 4 5 5 5 6 4 2 3 3 2 2 3
Depreciation 7 8 8 9 9 9 11 10 10 11 12 12
Profit before tax -178 81 43 -49 54 62 55 37 60 31 36 22
Tax % 6% 35% 32% 18% 23% 18% 25% 26% 25% 25% 22% 30%
-190 53 29 -58 42 50 41 28 45 23 28 15
EPS in Rs -13.26 3.69 2.05 -4.05 2.84 3.20 2.62 1.75 2.85 1.49 1.79 0.97
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
596 683 737 837 1,162 1,287 1,444 1,312 1,349
521 603 697 811 1,524 1,045 1,570 1,177 1,251
Operating Profit 75 80 40 27 -362 242 -126 135 97
OPM % 13% 12% 5% 3% -31% 19% -9% 10% 7%
55 58 66 -195 58 -48 74 128 106
Interest 3 4 4 1 4 13 18 15 10
Depreciation 23 23 25 26 28 30 33 40 46
Profit before tax 105 112 76 -195 -335 150 -103 208 148
Tax % 35% 33% 33% -26% 14% 17% 61% 23% 25%
68 75 51 -145 -382 125 -165 161 112
EPS in Rs 576.34 636.94 391.05 -1,118.18 -53.37 8.77 -11.56 10.23 7.09
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 41%
Compounded Sales Growth
10 Years: %
5 Years: 10%
3 Years: 2%
TTM: 3%
Compounded Profit Growth
10 Years: %
5 Years: 1%
3 Years: -20%
TTM: -28%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -5%
Return on Equity
10 Years: %
5 Years: -1%
3 Years: 3%
Last Year: 5%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 1 1 1 1 14 29 29 31 31
Reserves 766 841 711 566 171 283 115 2,275 2,397
33 51 36 41 140 146 267 46 59
160 153 678 690 1,488 1,437 1,684 333 326
Total Liabilities 960 1,046 1,426 1,298 1,814 1,894 2,095 2,685 2,812
236 237 242 244 253 272 317 356 426
CWIP 0 0 1 1 1 16 9 57 52
Investments 4 4 65 149 141 139 139 366 366
720 806 1,118 903 1,419 1,466 1,631 1,906 1,969
Total Assets 960 1,046 1,426 1,298 1,814 1,894 2,095 2,685 2,812

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-22 56 228 94 248 91 -2
-242 -100 -298 -202 -165 -459 -25
302 3 95 90 -21 375 -3
Net Cash Flow 38 -42 25 -18 62 8 -30
Free Cash Flow -53 27 200 -9 177 -3 -123
CFO/OP 62% 226% -65% 51% -225% 104% 35%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 74 85 88 92 95 73 59 57 59
Inventory Days 123 93 96 67 85 91 68 92 101
Days Payable 87 60 85 63 120 82 69 100 89
Cash Conversion Cycle 110 118 99 96 61 82 58 49 71
Working Capital Days 109 103 121 89 -2 4 -11 47 67
ROCE % 14% 10% 8% -71% 79% -15% 16% 7%

Insights

In beta
Mar 2016 Mar 2018 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Total Formulations Installed Production Capacity
Million Units

Log in to view insights

Please log in to see hidden values.

Login
Number of Manufacturing Facilities
Units
CDMO Customer Count
Units
Combined Capacity Utilization - Oral Solids
%
Combined Capacity Utilization - Sterile
%
Production Share of Total Drugs Consumed in India
%
R&D Spend as % of Adjusted Revenue
%
Number of SKUs
Units
DCGI Approvals
Units
Indian Domestic CDMO Market Share (by Value)
%
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
75.26% 75.26% 75.26% 75.26% 75.26% 75.26% 75.26%
7.34% 6.36% 5.77% 4.24% 2.27% 1.14% 1.38%
7.53% 6.99% 7.39% 8.85% 9.28% 14.41% 14.36%
7.14% 8.64% 8.84% 8.92% 10.46% 6.45% 6.29%
2.73% 2.73% 2.73% 2.73% 2.73% 2.73% 2.73%
No. of Shareholders 57,53168,41069,36669,42475,36576,86972,589

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls